A randomised controlled trial of oxytocin 5 IU versus oxytocin 5 IU and 30 IU infusion for the control of blood loss at elective caesarean section - pilot study. - caesarean third stage trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001361-34-GB

Enrollment

Registered

2005-03-31

Start date

2005-04-26

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective lower segment caesarean section

Interventions

Trade Name: Syntocinon Product Name: Syntocinon Pharmaceutical Form: Concentrate for solution for infusion Concentration unit: IU/ml international unit(s)/millilitre Concentration number: 5- Trade Na

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy women at term (> 36 weeks) with a singleton pregnancy booked for an elective caesarean section Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: placenta praevia; multiple pregnancy; known coagulopathy; current anti-coagulant therapy; thrombocytopenia

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate whether an infusion of oxytocin reduces blood loss at caesarean section;Secondary Objective: To quantify side effects of an oxytocin infusion at caesarean section;Primary end point(s): Estimated mean operative blood loss; incidence of side effects	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026